secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2025-02-19T23:59:59+00:00
Accession:  0001048477-25-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin reports Q4 revenue $747M (+16%), full-year GAAP EPS $2.21, guides 2025 rev growth ~10%
--------------------------------------------------------------------------------

- Q4 total revenue $747M (+16% YoY); full-year $2.854B (+18%). GAAP diluted EPS $0.64 (Q4) and $2.21 (FY), up 154% YoY.
- Non-GAAP diluted EPS $0.92 (Q4) and $3.52 (FY), up 69% YoY. Non-GAAP operating margin 28.6% for FY, up 9.2 ppts.
- VOXZOGO revenue $208M in Q4 (+42%), $735M full-year (+56%); on track for >25% CAGR 2023-2027.
- FY 2025 guidance: total revenue growth ~10% at midpoint; non-GAAP diluted EPS growth ~22%; targeting $4B revenue by 2027.
- Pipeline: BMN 333 (CNP) first-in-human dosed, BMN 351 DMD data H2 2025; PALYNZIQ adolescent study data mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000004/0001048477-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000004/bmrn-20250219.htm
  HTML page:      https://secwatch.observer/filing/0001048477-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer